Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

PURPOSE: We assessed pulmonary toxicity of cyclin-dependent kinase (CDK)4/6 inhibitors by analyzing the publicly available FDA Adverse Event Reporting System (FAERS). METHODS: Reports of interstitial lung disease (ILD) were characterized in terms of demographic information, including daily dose, lat...

Descripción completa

Detalles Bibliográficos
Autores principales: Raschi, Emanuel, Fusaroli, Michele, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641870/
https://www.ncbi.nlm.nih.gov/pubmed/33150548
http://dx.doi.org/10.1007/s10549-020-06001-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641870/
https://www.ncbi.nlm.nih.gov/pubmed/33150548
http://dx.doi.org/10.1007/s10549-020-06001-w

Ejemplares similares